Story

Formycon Boosts H1 Revenue to €25.8M, Narrows EBITDA Loss on Biosimilar Progress

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20261 min read
Formycon Boosts H1 Revenue to €25.8M, Narrows EBITDA Loss on Biosimilar Progress
Text size
Background

German biosimilar developer Formycon AG (FYB) announced a significant increase in first-half revenue and a narrower loss, according to its latest financial report. The company's improved performance was driven by key partnership payments related to its drug pipeline and a reduction in research expenses.

H1 Financial Performance

For the first six months of 2026, Formycon posted strong top-line growth and a notable improvement in profitability.

  • Revenue: Reached €25.8 million, a sharp increase from the prior-year period.
  • EBITDA Loss: Narrowed to €3.4 million, reflecting an improvement from the loss recorded in the first half of the previous year.

This positive trend was attributed to a combination of higher income and more efficient cost management, according to the company's filing.

Revenue Drivers and Cost Controls

Sample IUX Markets – In-articleAd

The revenue surge was primarily fueled by milestone and upfront payments from commercialization and development partnerships for its FYB206 biosimilar. Formycon also recorded increased royalty income and milestone payments from its FYB202 product, despite what it described as challenging market conditions.

The narrower loss was supported by lower research and development (R&D) costs. The company stated that these expenses declined as projects progressed through the development cycle, allowing for the capitalization of certain costs. During the period, Formycon also successfully completed clinical development for FYB206.

Full-Year Guidance Reaffirmed

Following its first-half results, Formycon confirmed its financial outlook for the full year 2026. The company projects its full-year revenue to be between €60 million and €70 million.

Group EBITDA for 2026 is expected to land in a range between €0 million and €10 million. Management anticipates that milestone payments for FYB206 and ongoing royalty income from FYB202 will be the main revenue drivers for the second half of the year.

Read next

More on Stocks
Back to latest news

LATEST